Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03149029
Title Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

melanoma

Therapies

Dabrafenib + Pembrolizumab + Trametinib

Pembrolizumab + Trametinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST